LSFG Repro: Reproducibility of Blood Flowmetry in Human Retina Using the Nidek Laser Speckle Flowgraphy LSFG-NAVI System

Sponsor
University of Zurich (Other)
Overall Status
Unknown status
CT.gov ID
NCT04014933
Collaborator
Cantonal Hosptial Aarau, Department of Ophthalmology, Aarau, Switzerland (Other)
150
2
30
75
2.5

Study Details

Study Description

Brief Summary

In addition to intraocular pressure blood perfusion pressure in the optic nerve is an important factor determing the cause of glaucoma. Increasing evidence suggests that in glaucoma patients retinal blood may be decreased.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: LASER SPECKLE FLOWGRAPHY

Detailed Description

According to the World Health Organization (WHO) glaucoma is the second leading cause of blindness. Glaucoma is a global problem, which is becoming even more important as the human life expectancy increases. Although the causes of glaucoma are uncertain, mainly intraocular pression (IOP), genetics, and ocular blood perfusion pressure in the optic nerve determine the cause of the disease. Increasing evidence suggests that in glaucoma patients retinal blood flow is decreased leading to progression and to damage of the optic nerve.

In order to measure the peripapillary blood flow a variety of devices using different techniques of flowmetry have been developed. In this study, the reproducibility of the retinal flowmetry measured with the LSFG-NAVI device from Nidek will be investigated. A high reproducibility is crucial for the clinical value of any measuring device.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Prospective, Non-randomised, Non-controlled Study of Reproducibility of Blood Flowmetry in Human Retina Using the Nidek Laser Speckle Flowgraphy LSFG-NAVI System
Actual Study Start Date :
Jul 1, 2019
Anticipated Primary Completion Date :
Feb 9, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
open-angle glaucoma

patients with a diagnosis of open-angle glaucoma, i.e. untreated IOP >21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma

Diagnostic Test: LASER SPECKLE FLOWGRAPHY
Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region

normal tension glaucoma

patients with a diagnosis of normal tension glaucoma, i.e. untreated IOP </=21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma

Diagnostic Test: LASER SPECKLE FLOWGRAPHY
Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region

healthy controls

individuals with normal optic disc and IOP </21mmHg and normal visual fields

Diagnostic Test: LASER SPECKLE FLOWGRAPHY
Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region

Outcome Measures

Primary Outcome Measures

  1. Coefficients of variation (COV) [1 month]

    COVs from 3 measurements of ocular blood flow at visit 1 of observer 1 and at visit 1 of observer 1 and from observer 2 will be computed.

  2. intraclass correlation coefficients (ICCs) [1 month]

    Intraobserver ICC, interobserver ICC, and inter-session ICC will be computed

Secondary Outcome Measures

  1. Cofounder [1 month]

    Blood pressure will be checked as potential cofounder

  2. Cofounder [1 month]

    heart rate will be checked as potential cofounder

  3. Cofounder [1 month]

    spherical equivalent will be checked as potential cofounder

  4. Cofounder [1 month]

    intraocular pressure will be checked as potential cofounder

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • signed Patient Informed Consent form

  • Be at least 18 years old

  • Diagnosis of primary or secondary open-angle glaucoma or normal tension glaucoma or healthy controls

Exclusion Criteria:
  • Age < 18 years

  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.

  • No vulnerable participants will be included in this study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cantonal Hospital Aarau, Department of Ophthalmology Aarau AG Switzerland 5001
2 Department of Ophthalmology Zurich ZH Switzerland 8091

Sponsors and Collaborators

  • University of Zurich
  • Cantonal Hosptial Aarau, Department of Ophthalmology, Aarau, Switzerland

Investigators

  • Principal Investigator: Marc Töteberg-Harms, MD, FEBO, UniversityHospital Zurich, Department of Ophthalmology, Zurich, Switzerland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Zurich
ClinicalTrials.gov Identifier:
NCT04014933
Other Study ID Numbers:
  • LSFG Repro
First Posted:
Jul 10, 2019
Last Update Posted:
Mar 25, 2020
Last Verified:
Mar 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Zurich
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 25, 2020